170 related articles for article (PubMed ID: 30695110)
1. Choice of first-line therapy in metastatic melanoma.
Gibney GT; Atkins MB
Cancer; 2019 Mar; 125(5):666-669. PubMed ID: 30695110
[No Abstract] [Full Text] [Related]
2. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
3. Research progress in advanced melanoma.
Luo C; Shen J
Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
[TBL] [Abstract][Full Text] [Related]
4. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Atkins MB
Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
[No Abstract] [Full Text] [Related]
5. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
6. ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more.
Stellato M; Santini D
Int Immunopharmacol; 2021 Sep; 98():107673. PubMed ID: 33935023
[No Abstract] [Full Text] [Related]
7. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
8. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D; Carvajal RD
Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma.
Dimitriou F; Matter AV; Mangana J; Urosevic-Maiwald M; Micaletto S; Braun RP; French LE; Dummer R
J Immunother; 2019 Jan; 42(1):29-32. PubMed ID: 29939877
[TBL] [Abstract][Full Text] [Related]
10. The future of combination treatment with checkpoint inhibitors in melanoma.
Sullivan RJ
Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111
[No Abstract] [Full Text] [Related]
11. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
Eiger D; Pondé NF; de Azambuja E
Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
14. Targeting complex, adaptive responses in melanoma therapy.
Cheng P; Levesque MP; Dummer R; Mangana J
Cancer Treat Rev; 2020 Jun; 86():101997. PubMed ID: 32179238
[TBL] [Abstract][Full Text] [Related]
15. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
16. Tackling melanoma by adjuvant therapy: why, whom and how?
Schilling B; Wiesner T
Br J Dermatol; 2019 Jan; 180(1):1-2. PubMed ID: 30604551
[No Abstract] [Full Text] [Related]
17. New therapies for anaplastic thyroid cancer.
Agrawal VR; Hreno J; Patil T; Bowles DW
Drugs Today (Barc); 2018 Nov; 54(11):695-704. PubMed ID: 30539168
[TBL] [Abstract][Full Text] [Related]
18. Management of Metastatic Melanoma in 2018.
Kaufman HL; Margolin K; Sullivan R
JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
[No Abstract] [Full Text] [Related]
19. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
20. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
[Next] [New Search]